The combination of subcutaneous daratumumab with VRd was approved in July 2024 for induction and consolidation in patients ...
Panelists discuss how integrating both intravenous (IV) and subcutaneous (SubQ) therapies in oncology centers requires adaptable staffing, data-driven workflow planning, and thoughtful pilot ...
Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results